Back to discover
Drug

Adavosertib

Early clinical development
ClassSerine/threonine-protein kinase WEE1 inhibitor
RxNorm2297975ChEMBLCHEMBL1976040UNIIK2T6HJX3I3
10
Active clinical trials
Wee1-like protein kinase
Primary target
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this drug.

Molecular Analysis for Therapy Choice (MATCH)

Clinical trial2026-08-04Results expected Q4 2026 · ClinicalTrials.gov

EFFORT: Efficacy of AZD1775 in Parp Resistance; A Randomized 2-Arm, Non-Comparative Phase 2 Study of AZD1775 Alone or AZD1775 and Olaparib in Women With Ovarian Cancer Who Have Progressed During PARP Inhibition

Clinical trial2026-07-16Results expected Q4 2026 · ClinicalTrials.gov

European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors

Clinical trial2026-07-10Results expected Q1 2031 · ClinicalTrials.gov

A Phase 1 Trial Combining WEE1 Inhibitor Adavosertib (AZD1775) With Radiation Therapy for Metastatic or Inoperable and Ineligible for Definitive Chemoradiation Esophageal and Gastroesophageal Junction Cancer

Clinical trial2026-06-22Results posted · ClinicalTrials.gov

Phase I Sequential Trial of Agents Against DNA Repair (STAR)

Clinical trial2026-06-17Results posted · ClinicalTrials.gov

MATCH Treatment Subprotocol Z1I: Phase II Study of AZD1775 in Patients With Tumors Containing BRCA1 and BRCA2 Mutations

Clinical trial2026-05-04Results expected Q4 2026 · ClinicalTrials.gov

A Pilot Study of Wee1 Inhibition Induction Prior to Tumor Reductive Surgery in Ovarian Cancer

Clinical trial2026-04-15Results expected Q4 2026 · ClinicalTrials.gov

A Randomized Placebo-Controlled Phase II Trial Comparing Gemcitabine Monotherapy to Gemcitabine in Combination With AZD 1775 (MK 1775) in Women With Recurrent, Platinum Resistant Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers

Clinical trial2026-04-13Results posted · ClinicalTrials.gov

A Phase 2 Study of AZD1775 in SETD2-Deficient Advanced Solid Tumor Malignancies

Clinical trial2026-03-01Primary completion · ClinicalTrials.gov

Phase I Study of AZD1775 (Adavosertib) With Radiation and Temozolomide in Patients With Newly Diagnosed Glioblastoma and Evaluation of Intratumoral Drug Distribution in Patients With Recurrent Glioblastoma

Clinical trial2024-10-30Completed · ClinicalTrials.gov

Prostate Cancer Biomarker Enrichment and Treatment Selection (PC-BETS) Study

Clinical trial2024-10-07Primary completion · ClinicalTrials.gov

A Phase 1 Study of AZD1775 (MK-1775) Concurrent With Local Radiation Therapy for the Treatment of Newly Diagnosed Children With Diffuse Intrinsic Pontine Gliomas

Clinical trial2024-01-31Results posted · ClinicalTrials.gov

Profile

Identifiers & mechanism

Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.

Canonical name
Adavosertib
RxNorm CUI
2297975
ChEMBL ID
CHEMBL1976040
UNII
K2T6HJX3I3
Primary mechanism
Serine/threonine-protein kinase WEE1 inhibitor

Pharmacology & targets

1 target

Known molecular targets and mechanisms supported by curated pharmacology databases.

Wee1-like protein kinase
WEE1 · P30291
INHIBITORSerine/threonine-protein kinase WEE1 inhibitor

Clinical trials

28 trials

The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.

Development programme
CLINICALTRIALS.GOV · LIVE REGISTRY
28
registered trials across all phases
LATEST COMPLETION 2024
10
Active studies
1
Recruiting
10
Completed
8
Discontinued
PHASE DISTRIBUTIONn = 28
Early Phase 11Phase 112Phase 1 / 23Phase 212

Recent completions

Trials that read out recently, adding to the completed evidence base.

Phase I Study of AZD1775 (Adavosertib) With Radiation and Temozolomide in Patients With Newly Diagnosed Glioblastoma and Evaluation of Intratumoral Drug Distribution in Patients With Recurrent Glioblastoma

CompletedPH INational Cancer Institute (NCI)n=742024

A Phase 1/2 Study of AZD1775 (MK-1775) in Combination With Oral Irinotecan in Children, Adolescents, and Young Adults With Relapsed or Refractory Solid Tumors

CompletedPH I/IINational Cancer Institute (NCI)n=762023

A Multicentre Phase II Study of Adavosertib Plus Chemotherapy in Patients With Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

CompletedPH IIAstraZenecan=952023

A Phase 2b, Open-label, Single-arm, Multi-centre Study Assessing the Efficacy and Safety of Adavosertib as Treatment for Recurrent or Persistent Uterine Serous Carcinoma

CompletedPH IIAstraZenecan=1092023

A Phase 2 Study of AZD1775, a Wee1 Inhibitor, in Patients With CCNE1 Amplification

CompletedPH IINational Cancer Institute (NCI)n=312022

A Phase 1 Study of AZD1775 (MK-1775) Concurrent With Local Radiation Therapy for the Treatment of Newly Diagnosed Children With Diffuse Intrinsic Pontine Gliomas

CompletedPH INational Cancer Institute (NCI)n=462022
References & data sources
  • RxNorm (U.S. National Library of Medicine) — drug identity
  • ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
  • ClinicalTrials.gov — clinical trials